Ariad Shareholders Sue Over Takeda Deal

(c) ER_09/Shutterstock
(c) ER_09/Shutterstock

On behalf of shareholders of Ariad Pharmaceuticals who claim their interests were not fairly represented in the sale of the company to Japanese drugmaker Takeda for $5.2 billion, at least two US law firms plan to pursue class action suits. 

In cooperation with the law firm Monteverde & Associates, New York City-headquartered national securities firm Nadeem Faruqi said it is investigating Ariad’s board of directors for potential breaches of fiduciary duties in connection with the sale of the company. The company's shareholders believe they should receive more than the $24 offered.

Faruqi said the investigation focuses on whether the board failed to conduct a fair sales process and whether and by how much this proposed transaction undervalues the company to the detriment of shareholders.

Separately, Wilmington, Delaware-based law firm Rigrodsky & Long has announced it is investigating potential legal claims against the Ariad board in the same sale process. The firm specializes in prosecuting securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation on behalf of shareholders throughout the US.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.